Compare LIF & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LIF | BEAM |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | 547 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.0B |
| IPO Year | N/A | 2019 |
| Metric | LIF | BEAM |
|---|---|---|
| Price | $48.18 | $30.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $75.58 | $50.75 |
| AVG Volume (30 Days) | 650.0K | ★ 1.8M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $36.21 | N/A |
| Revenue Next Year | $20.80 | $33.77 |
| P/E Ratio | $425.29 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $37.01 | $15.60 |
| 52 Week High | $112.54 | $36.44 |
| Indicator | LIF | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 60.49 | 52.91 |
| Support Level | $37.47 | $26.96 |
| Resistance Level | $48.37 | $33.32 |
| Average True Range (ATR) | 2.54 | 2.16 |
| MACD | 0.29 | -0.11 |
| Stochastic Oscillator | 82.84 | 44.32 |
Life360 is the world's largest family focused social network, with nearly 100 million monthly active users. Security-conscious families use the Life360 app to track each other's whereabouts and to track the location of their pets and personal belongings. Life360 also offers a suite of additional security features, such as driver safety monitoring, roadside assistance, and emergency dispatching. In the US, the Life360 app regularly ranks in the top 10 most popular social-networking apps and in the top 25 across all apps in terms of daily active users.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.